FY2025 EPS Estimates for Illumina Lifted by Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Investment analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for shares of Illumina in a research note issued on Friday, May 9th. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will post earnings per share of $4.26 for the year, up from their previous estimate of $4.22. The consensus estimate for Illumina’s current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina’s Q1 2026 earnings at $0.90 EPS, Q2 2026 earnings at $1.03 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.44 EPS and FY2026 earnings at $4.54 EPS.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the prior year, the company earned $0.98 earnings per share. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis.

A number of other equities research analysts have also weighed in on ILMN. Guggenheim cut their target price on shares of Illumina from $122.00 to $114.00 and set a “buy” rating on the stock in a research note on Friday. Barclays cut their price objective on Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a research report on Thursday, April 10th. HSBC lowered Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price for the company. in a research report on Friday, February 28th. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and dropped their price target for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Piper Sandler upped their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

Illumina Stock Down 4.8%

Shares of Illumina stock opened at $75.76 on Monday. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a market cap of $11.99 billion, a P/E ratio of -9.86, a PEG ratio of 1.60 and a beta of 1.35. The company’s fifty day simple moving average is $78.94 and its two-hundred day simple moving average is $113.12.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Rakuten Securities Inc. grew its holdings in shares of Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock valued at $29,000 after buying an additional 270 shares during the last quarter. Golden State Wealth Management LLC bought a new position in Illumina in the 4th quarter valued at approximately $32,000. Center for Financial Planning Inc. purchased a new stake in Illumina during the 1st quarter valued at $33,000. Fourth Dimension Wealth LLC bought a new stake in shares of Illumina in the 4th quarter worth $40,000. Finally, PFS Partners LLC raised its stake in shares of Illumina by 400.0% in the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after purchasing an additional 400 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.